Lenalidomide Associated With Second Primary Malignancies in MM, Not Other Cancers
Lenalidomide increases the risk of developing a second primary malignancy in patients with multiple myeloma, a meta-analysis suggests.
Multiple Myeloma News
MULTIPLE MYELOMA ADVISOR
Multiple Myeloma News
Isatuximab Plus RVd Dubbed New Standard Care in Newly Diagnosed Multiple Myeloma
Adding isatuximab to RVd improves the rate of MRD negativity in patients with newly diagnosed, transplant-eligible multiple myeloma, a phase 3 trial suggests.
T-Cell Engaging Therapies Show Promise as Salvage After CAR-T Therapy in MM
Patients with multiple myeloma that relapses after BCMA-directed CAR T-cell therapy may benefit from salvage treatment with additional T cell-engaging therapies.
Older MM Patients Have More Advanced Disease, Worse Outcomes in Real World vs RCTs
Multiple myeloma patients age 75 and older present with more advanced disease and have worse outcomes in the real world than in clinical trials, a study suggests.
Cilta-Cel May Fulfill Unmet Need for Multiple Myeloma Patients in China
Ciltacabtagene autoleucel had a favorable risk-benefit profile in a study of Chinese patients with relapsed/refractory multiple myeloma, according to researchers.
Proton FLASH Radiotherapy Deemed Feasible, Comparable to Conventional Dose Rate Radiotherapy
Proton FLASH radiotherapy is feasible, safe, and provides pain relief for cancer patients with bone metastases, according to a first-in-human trial.
Tecvayli Approved for Relapsed or Refractory Multiple Myeloma
The approval was based on data from the MajesTEC-1 study, which included 110 adults with relapsed or refractory multiple myeloma who had previously received at least 3 prior therapies.
Oncology Care Model Failed to Account for Patient and Disease Complexity, Researchers Say
Critical variables for 3 of the highest-volume cancers were not measured under the Oncology Care Model, according to researchers.
Iberdomide Plus Dexamethasone Elicits Responses in Relapsed/Refractory MM
Iberdomide plus dexamethasone demonstrated “meaningful” clinical activity in relapsed/refractory multiple myeloma, according to researchers.
Blood Test Shows Promise for Detecting Cancers Without Approved Screening Tests
A novel blood test can detect cancers that currently have no standard screening procedures, a study suggests.
SC Daratumumab “Preferable” to IV in Relapsed or Refractory Multiple Myeloma
SC and IV daratumumab produce similar efficacy outcomes, but infusion-related reactions are reduced with SC daratumumab.
GPRC5D May Be Promising New Target for CAR T-Cell Therapy in Multiple Myeloma
GPRC5D-targeted CAR T-cell therapy may be a promising treatment for heavily pretreated multiple myeloma, a phase 1 trial suggests.
Treatment Advances Have Improved Multiple Myeloma Mortality in the US
Researchers analyzed mortality trends among patients with multiple myeloma from 1975 to 2019.
T-Cell Redirection Therapy Studied for Relapsed Multiple Myeloma
The sequential use of different T-cell therapies may lead to durable responses following relapse after bispecific antibody therapy.
Access to Trials of CAR T-Cell Therapy or Bispecific Antibodies May Vary by Race
Black patients with multiple myeloma may not have equitable access to clinical trials of CAR T-cell therapy or bispecific antibodies.
Conditioning Regimens Produce Similar Long-Term Outcomes in Newly Diagnosed Multiple Myeloma
Conditioning with MEL200 or BUMEL produced similar outcomes at 7 years.
Risk for MGUS Up in WTC-Exposed Rescue/Recovery Workers
A new study supports prior reports suggesting that World Trade Center rescue/recovery workers have an increased risk of monoclonal gammopathy of undetermined significance.
Data Support Daratumumab for Transplant-Eligible, Newly Diagnosed Multiple Myeloma
Final results from the GRIFFIN trial support adding daratumumab to induction, consolidation, and maintenance therapy for patients with newly diagnosed, transplant-eligible multiple myeloma.
Isatuximab Provides “Clinically Meaningful” OS Benefit in Rel/Ref Multiple Myeloma
Final results from ICARIA-MM support isatuximab plus pomalidomide and dexamethasone as a standard of care for relapsed/refractory multiple myeloma, according to researchers.
Clinical Trials Not Representative of Population With Leukemia, Multiple Myeloma
Women were underrepresented in AML trials, and men were underrepresented in MM and CML trials.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma News
Loading... 
Loading...